Germany's ITM announces key appointments

By staff writers

February 4, 2022 -- German radiopharmaceutical biotechnology company ITM Isotope Technologies Munich has appointed three executives to lead the vendor's expansion in the U.S.

The newly appointed U.S. team includes the following:

  • Robert Sgroi, head of marketing and sales
  • Ian Clarke, head of market access
  • Dr. Val Nassiri, head of medical affairs

The team's main goal is to advance ITM's radiopharmaceutical pipeline and prepare for U.S. market entry, sales, and distribution of ITM's pipeline of candidates for targeted radionuclide therapies, the company said. Those candidates include ITM-11 (Lu-177 edotreotide), ITM's candidate for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ITM-11 is currently being evaluated in two phase III clinical studies.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking